Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Aug 10;8(8):e2983. doi: 10.1038/cddis.2017.386

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s)

Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

CDDO-Im pretreatment attenuates I/R injury. (a,b) Time-course (0–24 h) and dose-response (0–10 mg/kg) of CDDO-Im pretreatment and Nrf2 target genes mRNA levels (n=3 per group). (c) Representative hematoxylin and eosin (HE)-stained sections (original magnification, × 100) and relevant average Suzuki score (d) at 0, 6, 12 h post reperfusion or sham controls. (mean±S.E.M., n=4–6 per group). (e) Serum ALT and AST levels at 0, 6, 12 h post reperfusion; mean±S.E.M., n=4–6 per group. **P<0.01, *P<0.05